A detailed history of Alpha Mark Advisors, LLC transactions in Sorrento Therapeutics, Inc. stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 2,135 shares of SRNE stock, worth $704. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,135
Previous 2,135 -0.0%
Holding current value
$704
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 19, 2024

SELL
N/A
-1,000 Reduced 31.9%
2,135 $0
Q4 2022

Feb 06, 2023

SELL
$0.74 - $1.83 $640 - $1,582
-865 Reduced 21.63%
3,135 $3,000
Q1 2022

May 02, 2022

BUY
$2.0 - $4.9 $5,000 - $12,250
2,500 Added 166.67%
4,000 $9,000
Q4 2021

Feb 09, 2022

BUY
$4.65 - $7.23 $6,975 - $10,845
1,500 New
1,500 $7,000

Others Institutions Holding SRNE

About Sorrento Therapeutics, Inc.


  • Ticker SRNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 449,952,000
  • Market Cap $148M
  • Description
  • Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...
More about SRNE
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.